Document is current
Any future updates will be listed below
-
Authors
Mosley, Philip E. https://orcid.org/0000-0003-1721-3419
van der Meer, Johan N.
Hamilton, Lachlan H. W.
Fripp, Jurgen
Parker, Stephen https://orcid.org/0000-0002-6022-3981
Jeganathan, Jayson
Breakspear, Michael https://orcid.org/0000-0003-4943-3969
Parker, Richard https://orcid.org/0000-0003-1451-5622
Holland, Rebecca
Mitchell, Brittany L. https://orcid.org/0000-0002-9050-1516
Byrne, Enda https://orcid.org/0000-0002-9491-7797
Hickie, Ian B. https://orcid.org/0000-0001-8832-9895
Medland, Sarah E. https://orcid.org/0000-0003-1382-380X
Martin, Nicholas G. https://orcid.org/0000-0003-4069-8020
Cocchi, Luca https://orcid.org/0000-0003-3651-2676
-
Funding
Funding for this research was provided by:
Wesley Medical Research
Department of Health, Queensland
- License Information
-
More Information
Article History
Received: 11 January 2024
Revised: 11 August 2024
Accepted: 14 August 2024
First Online: 27 August 2024
Competing interests
: IBH has previously led pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca, Janssen Cilag) projects focused on the identification and better management of anxiety and depression. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd which aims to transform mental health services through the use of innovative technologies. All other authors have no conflicts of interest to report.
